YorkBridge Wealth Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

YorkBridge Wealth Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-800	Closed	-$84K	–	465
2019 Q2	$84K	Hold	800	–	–	0.04%	311
2019 Q1	$100K	Hold	800	–	–	0.05%	274
2018 Q4	$90K	Hold	800	–	–	0.05%	263
2018 Q3	$170K	Hold	800	–	–	0.08%	189
2018 Q2	$224K	Buy	+800	New	+$140K	0.1%	165

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

YorkBridge Wealth Partners's MDGL Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2019, closing a stake of 800 shares — an estimated $84K sold.

YorkBridge Wealth Partners first reported a position in MDGL in Q2 2018 and held it in 5 quarters. The position peaked at $224K in Q2 2018. 111 funds tracked by Wall St. Rank hold MDGL as of Q3 2019.

YorkBridge Wealth Partners reported no remaining Madrigal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
YorkBridge Wealth Partners sold 800 Madrigal Pharmaceuticals shares in Q3 2019, an estimated $84K.
YorkBridge Wealth Partners first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 5 quarters.
YorkBridge Wealth Partners's Madrigal Pharmaceuticals position peaked at $224K in Q2 2018.
111 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.